Roche Holding AG (0TDF.L)
| Previous close | 39.35 |
| Open | 40.67 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 40.67 - 40.67 |
| 52-week range | 32.09 - 40.67 |
| Volume | |
| Avg. volume | 352 |
| Market cap | 277.013B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 0.20 |
| EPS (TTM) | 2.07 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Investor's Business DailyAstraZeneca Says It Has A 'Powerful' — And Differentiated — Approach To Obesity Treatment
AstraZeneca stock skidded Thursday despite strong quarterly sales as an FDA panel met to discuss its lung cancer treatment.
ZacksRoche (RHHBY) Sales, Earnings Grow in 1H24, '24 EPS View Raised
Roche (RHHBY) records impressive second-quarter and first-half 2024 performance on the back of strong demand for drugs and tests. Consequently, the company raises its annual earnings guidance.
ReutersRoche lifts 2024 profit guidance on strong drug sales
FRANKFURT (Reuters) -Roche on Thursday raised its full-year earnings forecast after exceeding expectations for the first half, driven by strong demand for newer drugs such as eye medicine Vabysmo. The Swiss drugmaker said it expects growth in adjusted earnings in the "high single-digit range", excluding the effect of currency swings and resolution of tax disputes in 2023, up from previous estimates of "mid single-digit" percentage growth. First-half adjusted operating profit gained 4% to 11.3 billion Swiss francs ($12.8 billion), the family-controlled drugmaker said on Thursday, beating analysts' consensus estimate of 10.5 billion, based on LSEG data.
